News

Thu, 28/03/2024
Final Symposium with leading experts in MS
After almost 12 years, our transregional Collaborative Research Center CRC TR-128 is coming to an end. To celebrate our achievements and successful collaborations in research of the immune system and multiple sclerosis, we are organizing a final symposium in 2024. Date: April 29 and 30, 2024 Venue: Castle of the Münster University, Schlossplatz 2, 48149 […]...more
Thu, 15/09/2022
Photo gallery: Inflammation & Imaging Symposium in the MIC building
Muenster. From September 12th to 14th scientists from Muenster University and their international guests discussed the latest developments in research on inflammation and the imaging of the immune system at the 2nd Inflammation & Imaging Symposium. The annual event is jointly organised by several research networks from Münster, among them the CRC/TRR 128 “Multiple Sclerosis”. […]...more
Tue, 28/06/2022
CRC Retreat in Münster
Muenster. After a long pause, more than 90 participants of the CRC joined in Muenster Factory Hotel to update on the latest developments. We heard the most recent on a selection of the CRC projects and there was also plenty of time for fruitful discussion and socializing in the evening....more


Tue, 21/04/2015 | Nina Wettschureck awarded prize for mechanistic elucidation of MS therapy

Nina Wettschureck (MPI Bad Nauheim) from the CRC-TR-128, together with Markus Schwaninger (University of Lübeck), has been awarded the Novartis prize for therapy-relevant pharmacological research. The prize, which carries a value of €10,000, was presented at the Annual Conference of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) on 12 March 2015 in Kiel.

More details can be found in this press release, and the research for which the prize was awarded was reported in the following publication in The Journal of Clinical Investigation:

Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, Köhl J, Offermanns S, Wettschureck N, Schwaninger M: Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. The Journal of Clinical Investigation. doi:10.1172/JCI72151